Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,025 public trials 2,027 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

NCT02631044

Conditions
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +15 more
Locations
  • Local Institution - 0006 Birmingham, Alabama, United States
  • Local Institution - 0007 Duarte, California, United States
  • Local Institution - 0010 San Francisco, California, United States
  • Local Institution - 0020 Aurora, Colorado, United States
View all 14 locations
View Trial Details
Completed

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

NCT02464228

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Stanford University Medical Center Palo Alto, California, United States
  • Yale University, Yale Cancer Center New Haven, Connecticut, United States
  • H. Lee Moffitt Cancer Center & Research Institute, Inc. Tampa, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 13 locations
View Trial Details
Completed

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

NCT01796171

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University Of Arkansas For Medical Sciences Little Rock, Arkansas, United States
  • Pacific Shores Medical Group Long Beach, California, United States
  • University of California, San Francisco (UCSF) San Francisco, California, United States
  • Boca Raton Regional Hospital Boca Raton, Florida, United States
View all 96 locations
View Trial Details
Completed

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

NCT03610724

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +17 more
Locations
  • Childrens Hospital Los Angeles Los Angeles, California, United States
  • UCSF Medical Center San Francisco, California, United States
  • Johns Hopkins Oncology Center ORA Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Dept.of DFCI Boston, Massachusetts, United States
View all 26 locations
View Trial Details

Related conditions